Andrea Jurgens, MD
Dermatology · Muskogee, OKNPI 1467806323
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,376, more than ten times the $122 reported in 2020.
Across 358 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- Johnson & Johnson$1K
- AbbVie$862
- Lilly USA, LLC$631
- Amgen$449
- Novartis$340
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,18695%
- Education$3045%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 43 | $1,326 |
| Johnson & Johnson | 42 | $1,031 |
| AbbVie(2 entities) | 49 | $862 |
| Lilly USA, LLC | 37 | $631 |
| Amgen | 29 | $449 |
| Novartis | 17 | $340 |
| Arcutis Biotherapeutics, Inc. | 32 | $244 |
| Dermavant Sciences, Inc. | 21 | $219 |
| E.r. Squibb & Sons, L.L.C. | 13 | $186 |
| Mayne Pharma Commercial LLC | 19 | $169 |
| UCB, Inc. | 7 | $142 |
| Sun Pharmaceutical Industries Inc. | 6 | $124 |
| Sanofi | 6 | $113 |
| Pfizer | 6 | $104 |
| Boehringer Ingelheim | 4 | $71 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Galderma Laboratories, L.p. | 3 | $53 |
| Dermira, Inc. | 2 | $40 |
| Sandoz | 2 | $39 |
| LEO Pharma Inc. | 2 | $38 |
| Incyte Corporation | 2 | $37 |
| EPI Health, LLC | 2 | $36 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Organogenesis Inc. | 1 | $22 |
| Botanix SB Inc | 1 | $20 |
| Biofrontera Inc. | 1 | $19 |
| Organon | 2 | $17 |
| Journey Medical Corporation | 1 | $15 |
| Strata Skin Sciences, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
How this compares
$6,490 in reported general payments places this provider in the 60th percentile of 114 dermatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 23 | $496,953 |
| TremfyaGuselkumab | 15 | $203,256 |
| Dupixent PenDupilumab | 38 | $153,725 |
| Taltz AutoinjectorIxekizumab | 14 | $92,403 |
| Dupixent SyringeDupilumab | 14 | $52,876 |
| Clobetasol Propionate | 316 | $15,789 |
| Tacrolimus | 54 | $6,618 |
| Ketoconazole | 271 | $5,317 |
| Metronidazole | 88 | $4,485 |
| Triamcinolone Acetonide | 267 | $3,874 |
| Fluorouracil | 40 | $2,742 |
| Doxycycline Hyclate | 131 | $2,705 |
| Clindamycin Phosphate | 87 | $2,372 |
| Tretinoin | 32 | $1,345 |
| Finasteride | 75 | $969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,031 | $203,25615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 dermatology providers in Oklahoma.
Other dermatology in Muskogee
- Thomas HallStillwater$633K
- George MonksTulsa$530K
- Yaohan LamOklahoma City$88K
- Kimberly JerdanOklahoma City$59K
- Mark DawkinsOklahoma City$56K
- Jeff AlexanderTulsa$41K
- Johnathan LedetTulsa$37K
- John AshleyTulsa$24K
- Thomas UriceNorman$23K
- Alison FischerTulsa$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.